Administration of 9-[2-(phosphonomethoxy)propyl]adenine (PMPA) for prevention of perinatal simian immunodeficiency virus infection in rhesus macaques

Koen K.A. Van Rompay, Marta Marthas, Jeffrey D. Lifson, Christopher J. Berardi, Gabriela M. Vasquez, Elmo Agatep, Zia A. Dehqanzada, Kenneth C. Cundy, Norbert Bischofberger, Niels C Pedersen

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

Simian immunodeficiency virus (SIV) infection of newborn macaques is a useful animal model to explore novel strategies to reduce perinatal human immunodeficiency virus (HIV) infection. The availability of two easily distinguishable virus isolates, SIVmac251 and the simian/human immunodeficiency virus chimera SHIV-SF33, allows tracing the source of infection following inoculation with both viruses by different routes. In the present study, we evaluated the efficacy of pre- and postinoculation treatment regimens with 9-[2-(phosphonomethoxy)propyl]adenine (PMPA) to protect newborn macaques against simultaneous oral SIVmac251 and intravenous SHIV-SF33 inoculation. Untreated newborns became persistently infected following virus inoculation. When three pregnant macaques were given a single subcutaneous dose of PMPA 2 hr before cesarean section, their newborns became SIV-infected following SIV and SHIV inoculation shortly after birth. In contrast, when four newborn macaques were inoculated simultaneously with SIV and SHIV, and started immediately on PMPA treatment for 2 weeks, only one animal became persistently SIV-infected; the remaining three PMPA-treated newborns, however, had some evidence of an initial transient virus infection but were seronegative and healthy at 8 months of age. Our data demonstrate that PMPA treatment can reduce perinatal SIV infection and suggest that similar strategies may also be effective against HIV.

Original languageEnglish (US)
Pages (from-to)761-773
Number of pages13
JournalAIDS Research and Human Retroviruses
Volume14
Issue number9
StatePublished - Jun 10 1998

Fingerprint

Simian Immunodeficiency Virus
Adenine
Virus Diseases
Macaca mulatta
Macaca
HIV
Viruses
Cesarean Section
Animal Models
Parturition
Infection

ASJC Scopus subject areas

  • Immunology
  • Infectious Diseases
  • Virology

Cite this

Administration of 9-[2-(phosphonomethoxy)propyl]adenine (PMPA) for prevention of perinatal simian immunodeficiency virus infection in rhesus macaques. / Van Rompay, Koen K.A.; Marthas, Marta; Lifson, Jeffrey D.; Berardi, Christopher J.; Vasquez, Gabriela M.; Agatep, Elmo; Dehqanzada, Zia A.; Cundy, Kenneth C.; Bischofberger, Norbert; Pedersen, Niels C.

In: AIDS Research and Human Retroviruses, Vol. 14, No. 9, 10.06.1998, p. 761-773.

Research output: Contribution to journalArticle

Van Rompay, KKA, Marthas, M, Lifson, JD, Berardi, CJ, Vasquez, GM, Agatep, E, Dehqanzada, ZA, Cundy, KC, Bischofberger, N & Pedersen, NC 1998, 'Administration of 9-[2-(phosphonomethoxy)propyl]adenine (PMPA) for prevention of perinatal simian immunodeficiency virus infection in rhesus macaques', AIDS Research and Human Retroviruses, vol. 14, no. 9, pp. 761-773.
Van Rompay, Koen K.A. ; Marthas, Marta ; Lifson, Jeffrey D. ; Berardi, Christopher J. ; Vasquez, Gabriela M. ; Agatep, Elmo ; Dehqanzada, Zia A. ; Cundy, Kenneth C. ; Bischofberger, Norbert ; Pedersen, Niels C. / Administration of 9-[2-(phosphonomethoxy)propyl]adenine (PMPA) for prevention of perinatal simian immunodeficiency virus infection in rhesus macaques. In: AIDS Research and Human Retroviruses. 1998 ; Vol. 14, No. 9. pp. 761-773.
@article{ab27a9c211ce4b4a877225ada263f7f9,
title = "Administration of 9-[2-(phosphonomethoxy)propyl]adenine (PMPA) for prevention of perinatal simian immunodeficiency virus infection in rhesus macaques",
abstract = "Simian immunodeficiency virus (SIV) infection of newborn macaques is a useful animal model to explore novel strategies to reduce perinatal human immunodeficiency virus (HIV) infection. The availability of two easily distinguishable virus isolates, SIVmac251 and the simian/human immunodeficiency virus chimera SHIV-SF33, allows tracing the source of infection following inoculation with both viruses by different routes. In the present study, we evaluated the efficacy of pre- and postinoculation treatment regimens with 9-[2-(phosphonomethoxy)propyl]adenine (PMPA) to protect newborn macaques against simultaneous oral SIVmac251 and intravenous SHIV-SF33 inoculation. Untreated newborns became persistently infected following virus inoculation. When three pregnant macaques were given a single subcutaneous dose of PMPA 2 hr before cesarean section, their newborns became SIV-infected following SIV and SHIV inoculation shortly after birth. In contrast, when four newborn macaques were inoculated simultaneously with SIV and SHIV, and started immediately on PMPA treatment for 2 weeks, only one animal became persistently SIV-infected; the remaining three PMPA-treated newborns, however, had some evidence of an initial transient virus infection but were seronegative and healthy at 8 months of age. Our data demonstrate that PMPA treatment can reduce perinatal SIV infection and suggest that similar strategies may also be effective against HIV.",
author = "{Van Rompay}, {Koen K.A.} and Marta Marthas and Lifson, {Jeffrey D.} and Berardi, {Christopher J.} and Vasquez, {Gabriela M.} and Elmo Agatep and Dehqanzada, {Zia A.} and Cundy, {Kenneth C.} and Norbert Bischofberger and Pedersen, {Niels C}",
year = "1998",
month = "6",
day = "10",
language = "English (US)",
volume = "14",
pages = "761--773",
journal = "AIDS Research and Human Retroviruses",
issn = "0889-2229",
publisher = "Mary Ann Liebert Inc.",
number = "9",

}

TY - JOUR

T1 - Administration of 9-[2-(phosphonomethoxy)propyl]adenine (PMPA) for prevention of perinatal simian immunodeficiency virus infection in rhesus macaques

AU - Van Rompay, Koen K.A.

AU - Marthas, Marta

AU - Lifson, Jeffrey D.

AU - Berardi, Christopher J.

AU - Vasquez, Gabriela M.

AU - Agatep, Elmo

AU - Dehqanzada, Zia A.

AU - Cundy, Kenneth C.

AU - Bischofberger, Norbert

AU - Pedersen, Niels C

PY - 1998/6/10

Y1 - 1998/6/10

N2 - Simian immunodeficiency virus (SIV) infection of newborn macaques is a useful animal model to explore novel strategies to reduce perinatal human immunodeficiency virus (HIV) infection. The availability of two easily distinguishable virus isolates, SIVmac251 and the simian/human immunodeficiency virus chimera SHIV-SF33, allows tracing the source of infection following inoculation with both viruses by different routes. In the present study, we evaluated the efficacy of pre- and postinoculation treatment regimens with 9-[2-(phosphonomethoxy)propyl]adenine (PMPA) to protect newborn macaques against simultaneous oral SIVmac251 and intravenous SHIV-SF33 inoculation. Untreated newborns became persistently infected following virus inoculation. When three pregnant macaques were given a single subcutaneous dose of PMPA 2 hr before cesarean section, their newborns became SIV-infected following SIV and SHIV inoculation shortly after birth. In contrast, when four newborn macaques were inoculated simultaneously with SIV and SHIV, and started immediately on PMPA treatment for 2 weeks, only one animal became persistently SIV-infected; the remaining three PMPA-treated newborns, however, had some evidence of an initial transient virus infection but were seronegative and healthy at 8 months of age. Our data demonstrate that PMPA treatment can reduce perinatal SIV infection and suggest that similar strategies may also be effective against HIV.

AB - Simian immunodeficiency virus (SIV) infection of newborn macaques is a useful animal model to explore novel strategies to reduce perinatal human immunodeficiency virus (HIV) infection. The availability of two easily distinguishable virus isolates, SIVmac251 and the simian/human immunodeficiency virus chimera SHIV-SF33, allows tracing the source of infection following inoculation with both viruses by different routes. In the present study, we evaluated the efficacy of pre- and postinoculation treatment regimens with 9-[2-(phosphonomethoxy)propyl]adenine (PMPA) to protect newborn macaques against simultaneous oral SIVmac251 and intravenous SHIV-SF33 inoculation. Untreated newborns became persistently infected following virus inoculation. When three pregnant macaques were given a single subcutaneous dose of PMPA 2 hr before cesarean section, their newborns became SIV-infected following SIV and SHIV inoculation shortly after birth. In contrast, when four newborn macaques were inoculated simultaneously with SIV and SHIV, and started immediately on PMPA treatment for 2 weeks, only one animal became persistently SIV-infected; the remaining three PMPA-treated newborns, however, had some evidence of an initial transient virus infection but were seronegative and healthy at 8 months of age. Our data demonstrate that PMPA treatment can reduce perinatal SIV infection and suggest that similar strategies may also be effective against HIV.

UR - http://www.scopus.com/inward/record.url?scp=17644445089&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17644445089&partnerID=8YFLogxK

M3 - Article

C2 - 9643376

AN - SCOPUS:17644445089

VL - 14

SP - 761

EP - 773

JO - AIDS Research and Human Retroviruses

JF - AIDS Research and Human Retroviruses

SN - 0889-2229

IS - 9

ER -